Literature DB >> 17158762

Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Michael W Yeh1, Jean-Philippe Rougier, Jin-Woo Park, Quan-Yang Duh, Mariwil Wong, Zena Werb, Orlo H Clark.   

Abstract

Mechanisms of invasion in thyroid cancer remain poorly understood. We hypothesized that signaling via the epidermal growth factor receptor (EGFR) stimulates thyroid cancer cell invasion by altering the expression and cleavage of matrix metalloproteinases (MMPs). Papillary and follicular carcinoma cell lines were treated with EGF, the EGFR tyrosine kinase inhibitor AG1478, and the MMP inhibitors GM-6001 and Col-3. Flow cytometry was used to detect EGFR. In vitro invasion assays, gelatin zymography, and quantitative reverse transcription-PCR were used to assess the changes in invasive behavior and MMP expression and activation. All cell lines were found to overexpress functional EGFR. EGF stimulated invasion by thyroid cancer cells up to sevenfold (P<0.0001), a process that was antagonized completely by AG1478 and Col-3, partially by GM-6001, but not by the serine protease inhibitor aprotinin. EGF upregulated expression of MMP-9 (2.64- to 8.89-fold, P<0.0001) and membrane type-1 MMP (MT1-MMP, 1.97- to 2.67-fold, P<0.0001). This effect was blocked completely by AG1478 and partially by Col-3. The activation of MMP-2 paralleled MT1-MMP expression. We demonstrate that MMPs are critical effectors of invasion in the papillary and follicular thyroid cancer cell lines studied. Invasion is regulated by signaling through EGFR, an effect mediated by augmentation of gelatinase expression and activation. MMP inhibitors and growth factor antagonists may be effective tumoristatic agents for the treatment of aggressive thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158762      PMCID: PMC2574514          DOI: 10.1677/erc.1.01226

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  41 in total

1.  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.

Authors:  P O-charoenrat; H Modjtahedi; P Rhys-Evans; W J Court; G M Box; S A Eccles
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Authors:  Cleo Mesa; Mana Mirza; Norisato Mitsutake; Maureen Sartor; Mario Medvedovic; Craig Tomlinson; Jeffrey A Knauf; Georg F Weber; James A Fagin
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion.

Authors:  A Zielke; S Hoffmann; U Plaul; Q Y Duh; O H Clark; M Rothmund
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

Review 4.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

Review 5.  Matrix metalloproteinases in tumor invasion.

Authors:  N Johansson; M Ahonen; V M Kähäri
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

6.  The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.

Authors:  Mahdhia Soula-Rothhut; Cyrille Coissard; Hervé Sartelet; Cédric Boudot; Georges Bellon; Laurent Martiny; Bernard Rothhut
Journal:  Exp Cell Res       Date:  2004-11-23       Impact factor: 3.905

7.  Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

Authors:  Bradley A Schiff; Andrea B McMurphy; Samar A Jasser; Maher N Younes; Dao Doan; Orhan G Yigitbasi; Seungwon Kim; Ge Zhou; Mahitosh Mandal; Benjamin N Bekele; F Christopher Holsinger; Steven I Sherman; Sai-Ching Yeung; Adel K El-Naggar; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

8.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

Authors:  Y Nobuhara; N Onoda; Y Yamashita; M Yamasaki; K Ogisawa; T Takashima; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

9.  Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases.

Authors:  P Harvey; I M Clark; M C Jaurand; R M Warn; D R Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  18 in total

Review 1.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

Review 2.  Novel treatments for anaplastic thyroid carcinoma.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Ilaria Ruffilli; Concettina La Motta; Sabrina Rosaria Paparo; Armando Patrizio; Roberto Vita; Salvatore Benvenga; Gabriele Materazzi; Poupak Fallahi; Alessandro Antonelli
Journal:  Gland Surg       Date:  2020-01

3.  Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.

Authors:  Sonja Šelemetjev; Aleksandar Bartolome; Tijana Išić Denčić; Ilona Đorić; Ivan Paunović; Svetislav Tatić; Dubravka Cvejić
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

Review 4.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

5.  Expression of RECK and matrix metalloproteinase-2 in ameloblastoma.

Authors:  Bin Zhang; Jin Zhang; Zhi-Ying Xu; Hong-Liang Xie
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

6.  Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.

Authors:  Lei Gong; Ping Chen; Xianjun Liu; Ying Han; Yanping Zhou; Weidong Zhang; Hong Li; Chuanjia Li; Jiang Xie
Journal:  Gland Surg       Date:  2012-05

7.  Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension.

Authors:  Megan R Haymart; Simone L Glinberg; Jing Liu; Rebecca S Sippel; Juan C Jaume; Herbert Chen
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

8.  The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2.

Authors:  Masanobu Tsubaki; Hiroshi Matsuoka; Chikako Yamamoto; Chisato Kato; Mitsuhiko Ogaki; Takao Satou; Tatsuki Itoh; Takashi Kusunoki; Yoshihiro Tanimori; Shozo Nishida
Journal:  Clin Exp Metastasis       Date:  2007-07-18       Impact factor: 5.150

9.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

10.  Olfactomedin-1 activity identifies a cell invasion checkpoint during epithelial-mesenchymal transition in the chick embryonic heart.

Authors:  Alejandro Lencinas; Danny C Chhun; Kelvin P Dan; Kristen D Ross; Elizabeth A Hoover; Parker B Antin; Raymond B Runyan
Journal:  Dis Model Mech       Date:  2012-12-20       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.